Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity treatments. Takeda paid the San Diego–based biotech $75 million ...

On the left of the image, fibrils from wild-type amylin are made up from layers containing two molecules that are stacked side by side. In the S20G variant, there is a third molecule per layer.

In addition, it stimulates another called amylin which also reduces hunger and slows stomach emptying. Results showed the drug also appeared to be safe and well-tolerated among the 16 people who ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...

A new family of drugs is changing the way scientists are thinking about obesity — and more uses are on the horizon ...

The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 ...

After selling his previous firm, The Medicines Company, to Novartis for $9.7 billion, Clive Meanwell is on to his next ...

Novo Nordisk is having a great start to the year, with the company reporting better than expected sales and profit growth in ...

Disclosure: J.B.B. has conducted research and/or served on advisory boards under contract between the University of North Carolina and Amylin, Becton Dickinson, Bristol-Myers Squibb, Hoffman ...

β-cell–Centric Construct: A Potential Model for the Classification of DM Given the above discussion, the issue is not "what is LADA" or any clinical presentation of DM under the current system.